

Postoperative pain - Pipeline Insight, 2021

<https://marketpublishers.com/r/P045C1AF0758EN.html>

Date: February 2021

Pages: 200

Price: US\$ 2,500.00 (Single User License)

ID: P045C1AF0758EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Postoperative pain - Pipeline Insight, 2021," report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Postoperative pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Postoperative pain Understanding

Postoperative pain: Overview

Postoperative pain (CINV) are the side effects of cancer chemotherapy that can cause significant negative impacts on patients' quality of life and on their ability to tolerate and comply with therapy. An estimated 80% of patients with cancer experience chemotherapy-induced nausea and vomiting. It includes emesis and nausea, which can involve a loss of appetite and result in decreased oral intake of fluids and calories. CINV can be classified into 5 types: acute, delayed, anticipatory, breakthrough, and refractory. The pathophysiology of CINV includes both peripheral and central nervous system (CNS) pathways with different mechanisms involved in acute CINV and delayed CINV. Risk factors for developing CINV can be classified as patient-related or treatment-related. Prevention is the primary goal in the management of CINV. The primary

alternative for prevention and treatment include 5-HT₃ receptor antagonists, NK1 receptor antagonists, and corticosteroids. Other medications used, but to a lesser extent, include dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine.

“Postoperative pain - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postoperative pain pipeline landscape is provided which includes the disease overview and Postoperative pain treatment guidelines. The assessment part of the report embraces, in depth Postoperative pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postoperative pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Postoperative pain R&D. The therapies under development are focused on novel approaches to treat/improve Postoperative pain.

Postoperative pain Emerging Drugs Chapters

This segment of the Postoperative pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postoperative pain Emerging Drugs

HTX-011: Heron Therapeutics

HTX-011 (bupivacaine and meloxicam) is an investigational drug and is in development to reduce postoperative pain for 72 hours and reduce the need for opioid analgesics. It is an extended-release, dual-acting local anesthetic (DALA) applied into the surgical site. It utilizes a novel, synergistic mechanism of action that combines bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam. In September 2020, the European Commission (EC) granted a marketing authorization for ZYNRELEF (formerly known as HTX-011) for the treatment of somatic postoperative

pain from small- to medium-sized surgical wounds in adults. In September 2020, based on USFDA meeting plans to resubmit the NDA for HTX-011 for the management of postoperative pain in the fourth quarter of 2020.

CR845: Cara Therapeutics

CR845 is a peripherally acting kappa opioid receptor agonist. CR845 displayed no significant affinity for any other non-opioid known receptors. CR845 exhibits potent analgesic, anti-pruritic (anti-itch) and anti-inflammatory properties in both human and animals. CR845 is intrinsically poor at penetrating the blood-brain barrier, that's why it has shown to produce little to no CNS-mediated side effects.

Further product details are provided in the report.....

Postoperative pain: Therapeutic Assessment

This segment of the report provides insights about the different Postoperative pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Postoperative pain

There are approx. 60+ key companies which are developing the therapies for Postoperative pain. The companies which have their Postoperative pain drug candidates in the most advanced stage, i.e. Registered include, Heron Therapeutics.

Phases

DelveInsight's report covers around 60+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Postoperative pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postoperative pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postoperative pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postoperative pain drugs.

Postoperative pain Report Insights

- Postoperative pain Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Postoperative pain Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Postoperative pain drugs?

How many Postoperative pain drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postoperative pain?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postoperative pain therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Postoperative pain and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Heron Therapeutics

Cara Therapeutics

Endo Pharmaceuticals

Mylan

Concentric Analgesics

Camurus

PainReform

Layerbio

Jiangsu HengRui Medicine

Polypid

Pharmaleads

Layerbio

Neumentum

Key Products

HTX-011

CR845

Oxymorphone

MR-107A-01

Vocacapsaicin

Buprenorphine depot

HTX-034

PRF 110

Ketorolac ophthalmic implant

Ropivacaine

Ketorolac ophthalmic implant

Research programme: controlled release pain therapeutics

PL-37

Ketorolac

Contents

Introduction

Executive Summary

Postoperative pain: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Postoperative pain – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Postoperative pain companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Postoperative pain Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Registered)

Comparative Analysis

HTX-011: Heron Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Late Stage Products (Phase III)

Comparative Analysis

CR 845: Cara Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

MR-107A-01: Mylan

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Ketorolac ophthalmic implant: Layerbio

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Comparative Analysis

TA-A002: TALLC Corporation

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Postoperative pain Key Companies

Postoperative pain Key Products

Postoperative pain- Unmet Needs

Postoperative pain- Market Drivers and Barriers

Postoperative pain- Future Perspectives and Conclusion

Postoperative pain Analyst Views

Postoperative pain Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Postoperative pain

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Postoperative pain

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Postoperative pain - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P045C1AF0758EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P045C1AF0758EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970